These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 33446189)

  • 1. Deciphering molecular mechanisms underlying chemoresistance in relapsed AML patients: towards precision medicine overcoming drug resistance.
    Levin M; Stark M; Ofran Y; Assaraf YG
    Cancer Cell Int; 2021 Jan; 21(1):53. PubMed ID: 33446189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
    Wells RJ; Adams MT; Alonzo TA; Arceci RJ; Buckley J; Buxton AB; Dusenbery K; Gamis A; Masterson M; Vik T; Warkentin P; Whitlock JA;
    J Clin Oncol; 2003 Aug; 21(15):2940-7. PubMed ID: 12885813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic hematopoietic cell transplantation in patients with AML not achieving remission: potentially curative therapy.
    Gyurkocza B; Lazarus HM; Giralt S
    Bone Marrow Transplant; 2017 Aug; 52(8):1083-1090. PubMed ID: 28244979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic overview of chemotherapy effects in acute myeloid leukaemia.
    Kimby E; Nygren P; Glimelius B;
    Acta Oncol; 2001; 40(2-3):231-52. PubMed ID: 11441935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same?
    Wolach O; Itchaki G; Bar-Natan M; Yeshurun M; Ram R; Herscovici C; Shpilberg O; Douer D; Tallman MS; Raanani P
    Hematol Oncol; 2016 Mar; 34(1):28-35. PubMed ID: 25689584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
    Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
    J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surmounting Cytarabine-resistance in acute myeloblastic leukemia cells and specimens with a synergistic combination of hydroxyurea and azidothymidine.
    Levin M; Stark M; Berman B; Assaraf YG
    Cell Death Dis; 2019 May; 10(6):390. PubMed ID: 31101804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lysosome-mediated chemoresistance in acute myeloid leukemia.
    Cuesta-Casanovas L; Delgado-Martínez J; Cornet-Masana JM; Carbó JM; Clément-Demange L; Risueño RM
    Cancer Drug Resist; 2022; 5(1):233-244. PubMed ID: 35582535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).
    Thiel A; Schetelig J; Pönisch W; Schäfer-Eckart K; Aulitzky W; Peter N; Schulze A; Maschmeyer G; Neugebauer S; Herbst R; Hänel A; Morgner A; Kroschinsky F; Bornhäuser M; Lange T; Wilhelm M; Niederwieser D; Ehninger G; Fiedler F; Hänel M; ;
    Ann Oncol; 2015 Jul; 26(7):1434-40. PubMed ID: 25922062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
    Narayan R; Blonquist TM; Emadi A; Hasserjian RP; Burke M; Lescinskas C; Neuberg DS; Brunner AM; Hobbs G; Hock H; McAfee SL; Chen YB; Attar E; Graubert TA; Bertoli C; Moran JA; Bergeron MK; Foster JE; Ramos AY; Som TT; Vartanian MK; Story JL; McGregor K; Macrae M; Behnan T; Wey MC; Rae J; Preffer FI; Lesho P; Duong VH; Mann ML; Ballen KK; Connolly C; Amrein PC; Fathi AT
    Cancer; 2020 Mar; 126(6):1264-1273. PubMed ID: 31860140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heme oxygenase-1 plays a crucial role in chemoresistance in acute myeloid leukemia.
    Zhe N; Wang J; Chen S; Lin X; Chai Q; Zhang Y; Zhao J; Fang Q
    Hematology; 2015 Aug; 20(7):384-91. PubMed ID: 26218201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modified cladribine, cytarabine, and G-CSF as a salvage regimen in patients with relapsed/refractory acute myeloid leukemia: a bridge to myeloablative allogeneic hematopoietic stem cell transplantation.
    Ye P; Pei R; Jin J; Sun J; Li K; Cao J; Zhou D; Lu Y
    Ann Hematol; 2019 Sep; 98(9):2073-2080. PubMed ID: 31201514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia.
    Roboz GJ; Rosenblat T; Arellano M; Gobbi M; Altman JK; Montesinos P; O'Connell C; Solomon SR; Pigneux A; Vey N; Hills R; Jacobsen TF; Gianella-Borradori A; Foss Ø; Vetrhusand S; Giles FJ
    J Clin Oncol; 2014 Jun; 32(18):1919-26. PubMed ID: 24841975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The thorny issue of relapsed acute myeloid leukemia.
    Kubal T; Lancet JE
    Curr Opin Hematol; 2013 Mar; 20(2):100-6. PubMed ID: 23385612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review.
    Megías-Vericat JE; Martínez-Cuadrón D; Sanz MÁ; Montesinos P
    Ann Hematol; 2018 Jul; 97(7):1115-1153. PubMed ID: 29680875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and emerging therapies for acute myeloid leukemia.
    Robak T; Wierzbowska A
    Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Relapsed/Refractory Acute Myeloid Leukemia.
    Bose P; Vachhani P; Cortes JE
    Curr Treat Options Oncol; 2017 Mar; 18(3):17. PubMed ID: 28286924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long non-coding RNA taurine-upregulated gene 1 correlates with unfavorable prognosis in patients with refractory or relapsed acute myeloid leukemia treated by purine analogue based chemotherapy regimens.
    Luo W; Yu H; Zou X; Ni X; Wei J
    Cancer Biomark; 2018; 23(4):485-494. PubMed ID: 30347595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel treatments for relapsed/refractory acute myeloid leukemia with
    Tallis E; Borthakur G
    Expert Rev Hematol; 2019 Aug; 12(8):621-640. PubMed ID: 31232619
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.